TRCT
GNMX

Tower Research Capital (TRC)’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Tower Research Capital (TRC)’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-141
Closed – – 4632
2018
Q4 		$0 Buy
+141
New +$157 ﹤0.01% 4658
2018
Q1 		– Sell
-61
Closed – – 4153
2017
Q4 		$0 Buy
+61
New +$83 ﹤0.01% 4304
2017
Q3 		– Sell
-10,365
Closed -$14K – 4328
2017
Q2 		$14K Buy
+10,365
New +$15K ﹤0.01% 1437
2017
Q1 		– Sell
-3,870
Closed -$20K – 4313
2016
Q4 		$20K Buy
+3,870
New +$20.4K ﹤0.01% 2167
2016
Q1 		– Sell
-528
Closed -$3K – 5316
2015
Q4 		$3K Sell
528
-1,387
-72% -$9.42K ﹤0.01% 3578
2015
Q3 		$15K Buy
1,915
+362
+23% +$2.81K ﹤0.01% 1997
2015
Q2 		$10K Buy
1,553
+1,457
+1,518% +$11.3K ﹤0.01% 2737
2015
Q1 		$1K Sell
96
-160
-63% -$1.21K ﹤0.01% 4216
2014
Q4 		$1K Buy
+256
New +$1.26K ﹤0.01% 3801
2013
Q3 		– Sell
-100
Closed – – 4985
2013
Q2 		$0 Buy
+100
New +$410 ﹤0.01% 4007

Other funds holding GNMX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tower Research Capital (TRC)'s GNMX Position: Q1 2019 in Review

Tower Research Capital (TRC) sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2019, closing a stake of 141 shares.

Tower Research Capital (TRC) first reported a position in GNMX in Q2 2013 and held it in 10 quarters. The position peaked at $20K in Q4 2016. 28 funds tracked by Wall St. Rank hold GNMX as of Q1 2019.

  • Tower Research Capital (TRC) reported no remaining Aevi Genomic Medicine Inc position as of Q1 2019 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 141 Aevi Genomic Medicine Inc shares in Q1 2019.
  • Tower Research Capital (TRC) first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 10 quarters.
  • Tower Research Capital (TRC)'s Aevi Genomic Medicine Inc position peaked at $20K in Q4 2016.
  • 28 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2019.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2019, filed 14 May 2019.